Percutaneous left atrial appendage closure (LAAC) is not inferior to direct oral anticoagulants (DOACs) in the prevention of major atrial fibrillation (AF)-related cardiovascular, neurological, and bleeding events, results of a recent study have shown.
Catheter ablation reduces recurrence of any atrial fibrillation (AF) by 48 percent and symptomatic AF by 51 percent compared with drug therapy over 5 years of follow-up, reports a study. Catheter ablation patients also have significantly lower AF burden regardless of baseline AF type.
Cardiovascular (CV) risk prediction algorithms tend to be inaccurate, frequently underestimating and sometimes overestimating the risk of CV in patients with inflammatory rheumatic diseases, a recent study has shown.
In morbidly obese hospitalized patients, high-fixed dose unfractionated heparin for the prevention of venous thromboembolism is associated with a higher risk of major bleeding events compared with high-fixed dose enoxaparin, a recent study has shown.
Among patients with asthma, heavy smoking appears to be an important risk factor for airflow reduction and fixed airflow obstruction, steroid insensitivity and specific comorbidities, but less allergy along with low fractional exhaled nitric oxide (FeNO) and blood eosinophils, according to a study.
The prevalence of several chronic conditions is higher in patients with heart failure (HF) than population controls, suggests a recent study. Such associations are also seen in those with reduced and preserved ejection fraction, except for hypertension, which is more strongly associated with HF with preserved ejection fraction.
Blood pressure (BP) control can be best achieved with a multilevel, multicomponent approach involving team-based care with physician- and non-physician-led interventions, as well as patient-level strategies, according to findings of a meta-analysis.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.